Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04555174 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion date: Jan 21, 2022 to Jan 18, 2023Trial status: Completed to Active, Not Recruiting · Study sites: 40 to 41 · Completion date: Jan 21, 2022 to Feb 19, 2027v6Show 3 more changesShow less
Trial status: Completed to Active, Not Recruiting
Study sites: 40 to 41
Completion date: Jan 21, 2022 to Feb 19, 2027
MinorTrial status: Recruiting to CompletedEnrollment target: estimated 868 to confirmed 872 · Study sites: 44 to 40 · Primary completion date changed from estimate of Mar 2023 to Jan 21, 2022 · 1 morev5Show 4 more changesShow less
Enrollment target: estimated 868 to confirmed 872
Study sites: 44 to 40
Primary completion date changed from estimate of Mar 2023 to Jan 21, 2022
Study completion date changed from estimate of Mar 2027 to Jan 21, 2022
MinorStudy sites: 31 to 44v4
MinorStudy sites: 34 to 31Eligibility criteria expanded, about 36 wordsv3Show 1 more changeShow less
NotableTrial status: Not Yet Recruiting to RecruitingStart date changed from estimate of Sep 2020 to Sep 25, 2020 · Site details revised at 34 of 34 sitesv2Show 2 more changesShow less
Start date changed from estimate of Sep 2020 to Sep 25, 2020
Site details revised at 34 of 34 sites
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The BIOFLOW-VIII registry is a post-market clinical evaluation of the Orsiro Mission stent in subjects requiring coronary revascularization with Drug Eluting Stents (DES).